Sustained drug delivery implant
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
1. A method comprising administering a solid intraocular implant to the vitreous of a human patient suffering from geographic atrophy, wherein the solid intraocular implant comprises:
a brimonidine free base in an amount of about 40% by weight to about 60% by weight of the implant, based on the total weight of the implant; and
a biodegradable polymer matrix comprising an acid end-capped poly (D, L-lactide) polymer and a 75:25 poly (D,L-lactide-co-glycolide) polymer;
wherein the implant has a brimonidine free base delivery duration of two months to four months when placed in the vitreous of a human; and
wherein the implant has a polymer matrix degradation time in the range of about three months to about six months when placed in the eye of a human.
2. The method of claim 1 , wherein the brimonidine free base is present in an amount of about 50% by weight of the implant, based on the total weight of the implant.
3. The method of claim 1 , wherein the total weight of the implant is about 800 μg.